-
1Academic Journal
Authors: K. M. Nyushko, A. A. Krasheninnikov, M. P. Golovaschenko, A. D. Kaprin, К. М. Нюшко, А. А. Крашенинников, М. П. Головащенко, А. Д. Каприн
Source: Research and Practical Medicine Journal; Том 1, № 1 (2014); 69-73 ; Research'n Practical Medicine Journal; Том 1, № 1 (2014); 69-73 ; 2410-1893 ; undefined
Subject Terms: кардиоваскулярный риск, analogues and antagonists of luteinizing hormone releasing hormone, the castration refractory, cardiovascular disease, cardiovascular risk, аналоги и антагонисты лютеинизирующего гормона релизинг гормона, кастрационная рефрактерность, сердечно-сосудистая патология
File Description: application/pdf
Relation: https://www.rpmj.ru/rpmj/article/view/20/12; Sostojanie onkologicheskoj pomoshhi naseleniju Rossii v 2012 godu [Kniga]//Pod red. A. D. Kaprina V. V. Starinskogo, G. V. Petrovoj. – M: FGBU «MNIOI im. P. A. Gercena» Minzdrava Rossii, 2013. – str. 128.; Huggins C, Hoges C. V. Studies on prostate cancer. The effect of castration [Journal]//Cancer Res. – 1941. – pp. 385–402.; Malkowicz S. B. The role of diethylstilbestrol in the treatment of prostate cancer [Journal]//Urology. – 2001. – Vol. 58. – pp. 108–13.; Alekseev B.Ja., Njushko K. M. Gormonal’naja terapija bol’nyh rakom predstatel’noj zhelezy [Zhurnal]//Onkourologija. – 2007 g. – T. 3. – str. 57–62.; Kaisary A. V., Tyrrell C. J., Peeling W. B. et al. Comparison of LHRH analogue with orchiectomy in patients with metastatic prostatic carcinoma [Journal]//Br J Urol. – 1991. – Vol. 67. – pp. 502–8.; Rusakov I. G., Alekseev B.Ja., Njushko K. M. Gormonal’naja terapija preparatom lejprorelin (ljukrin-depo®) u bol’nyh rakom predstatel’noj zhelezy [Zhurnal]//Onkourologija. – 2009 g. – T. 3. – str. 56–60.; Alekseev B.Ja., Njushko K. M., Vorob’ev N. V. i dr. Chastota i lokalizacija metastazov v limfaticheskih uzlah pri vypolnenii radikal’noj prostatjektomii i rasshirennoj tazovoj limfadenjektomii u bol’nyh rakom predstatel’noj zhelezy [Zhurnal]//Onkourologija. – 2012 g. – T. 1. – str. 77–82.; Alekseev B.Ja., Njushko K. M. Rasshirennaja tazovaja limfadenjektomija pri hirurgicheskom lechenii raka predstatel’noj zhelezy [Zhurnal]//Vrach. – 2010 g. – T. 11. – str. 63–64.; Alekseev B.Ja., Njushko K. M. Ad#juvantnaja gormonal’naja terapija kak metod radikal’nogo lechenija u bol’nyh mestno-rasprostranennym rakom predstatel’noj zhelezy [Zhurnal]//Onkourologija. – 2007 g. – T. 2. – str. 61–63.; Alekseev B.Ja., Njushko K. M. Radikal’naja prostatjektomija s rasshirennoj tazovoj limfadenjektomiej i ad#juvantnaja gormonal’naja terapija u bol’nyh limfogenno-disseminirovannym rakom predstatel’noj zhelezy [Zhurnal]//Onkourologija. – 2011 g. – T. 3. – str. 118–121.; Keating N. L., O’Malley A. J., Freedland S. J. et al. Diabetes and Cardiovascular Disease During Androgen Deprivation Therapy: Observational Study of Veterans With Prostate Cancer [Journal]// J Natl Cancer Inst. – 2010. – Vol. 102. – pp. 39–46.; Bubley G. J. Is the flare phenomenon clinically significant? [Journal]//Urology. – 2001. – Vol. 58. – pp. 5–9.; Bertaglia V., Tucci M., Fiori C. et al. Effects of serum testosterone levels after 6 months of androgen deprivation therapy on the outcome of patients with prostate cancer [Journal]//Clin Genitourin Cancer. – 2013. – Vol. 11. – pp. 325–330.; Rick F. G., Block N. L., Schally A. V. An update on the use of degarelix in the treatment of advanced hormone-dependent prostate cancer [Journal]//Onco Targets Ther. – 2013. – Vol. 16. – pp. 391–402.; Anderson J. Degarelix: a novel gonadotropin-releasing hormone blocker for the treatment of prostate cancer [Journal]//Future Oncol. – 2009. – Vol. 5. – pp. 433–43.; Persson B. E., Kold Olesen T., Jensen J. K. Degarelix: a new approach for the treatment of prostate cancer [Journal]//Neuroendocrinology. – 2009. – Vol. 90. – pp. 235–44.; Klotz L., Boccon-Gibod L., Shore N. D. et al. The efficacy and safety of degarelix: a 12‑month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. [Journal]//BJU Int. – 2008. – Vol. 102. – pp. 1531–8.; Crawford E. D., Shore N. D., Moul J. W. et al. Long-term tolerability and efficacy of degarelix: 5‑year results from a phase III extension trial with a 1‑arm crossover from leuprolide to degarelix [Journal]//Urology. – 2014. – Vol. 83. – pp. 1122–8.; Klotz L., Miller K., Crawford E. D. et al. Disease Control Outcomes from Analysis of Pooled Individual Patient Data from Five Comparative Randomised Clinical Trials of Degarelix Versus Luteinising Hormone-releasing Hormone Agonists [Journal]//Eur Urol. – 2014. – Vol. 66. – pp. 1101–8.; Kurt Miller, Christoph Rüssel, Sandra Goble et al. Open-label, exploratory study of degarelix as second-line hormonal therapy in patients with prostate cancer (CS27)//Poster 678. – [s. l.]: EAU, 2013.; Van Poppel H1, Klotz L. Gonadotropin-releasing hormone: an update review of the antagonists versus agonists [Journal]//Int J Urol. – 2012. – Vol. 19. – pp. 594–601.; Smith M. R.1, Klotz L., van der Meulen E. et al. Gonadotropin-releasing hormone blockers and cardiovascular disease risk: analysis of prospective clinical trials of degarelix [Journal]//J Urol. – 2011. – Vol. 186. – pp. 1835–42.; Tanriverdi F., Gonzalez-Martinez D., Hu Y. et al. GnRH-I and GnRHII have differential modulatory effects on human peripheral blood mononuclear cell proliferation and interleukin‑2 receptor gamma-chain mRNA expression in healthy males [Journal]//Clin Exp Immunol. – 2005. – Vol. 142. – pp. 103–10.; Chen H. F., Jeung E. B., Stephenson M., Leung P. C. Human peripheral blood mononuclear cells express gonadotropin-releasing hormone (GnRH), GnRH receptor, and interleukin‑2 receptor gamma-chain messenger ribonucleic acids that are regulated by GnRH in vitro [Journal]//J Clin Endocrinol Metab. – 1999. – Vol. 84. – pp. 743–50.; https://www.rpmj.ru/rpmj/article/view/20
-
2Academic Journal
Authors: K. M. Nyushko, B. Ya. Alekseev, A. S. Kalpinsky, A. D. Kaprin, К. М. Нюшко, Б. Я. Алексеев, А. С. Калпинский, А. Д. Каприн
Source: Cancer Urology; Том 10, № 4 (2014); 70-74 ; Онкоурология; Том 10, № 4 (2014); 70-74 ; 1996-1812 ; 1726-9776 ; 10.17650/1726-9776-2014-10-4
Subject Terms: кардиоваскулярный риск, luteinizing hormone-releasing hormone analogues and antagonists, degarelix, castration-refractoriness, cardiovascular disease, cardiovascular risk, аналоги и антагонисты лютеинизирующего гормона рилизинг-гормона, дегареликс, кастрационная рефрактерность, сердечно-сосудистая патология
File Description: application/pdf
Relation: https://oncourology.abvpress.ru/oncur/article/view/399/416; Состояние онкологической помощи населению России в 2012 году. Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М., 2013.; Huggins C., Hoges C.V. Studies on prostate cancer. The effect of castration. Cancer Res 1941:385–402.; Malkowicz S.B. The role of diethylstilbestrol in the treatment of prostate cancer. Urology 2001;58(2 Suppl 1):108–13.; Kaisary A.V., Tyrrell C.J., Peeling W.B. et al. Comparison of LHRH analogue with orchiectomy in patients with metastatic prostatic carcinoma. Br J Urol 1991;67(5):502–8.; Keating N.L., O'Malley A.J., Freedland S.J. et al. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. JNCI J Natl Cancer Inst 2010;102:39–46.; Bubley G.J. Is the flare phenomenon clinically significant? Urology 2001;58 (2 Suppl 1):5–9.; Bertaglia V., Tucci M., Fiori C. et al. Effects of serum testosterone levels after 6 months of androgen deprivation therapy on the outcome of patients with prostate cancer. Clin Genitourin Cancer 2013;11(3):325–30.; Rick F.G., Block N.L., Schally A.V. An update on the use of degarelix in the treatment of advanced hormone-dependent prostate cancer. Onco Targets Ther 2013;6:391–402.; Anderson J. Degarelix: a novel gonadotropin-releasing hormone blocker for the treatment of prostate cancer. Future Oncol 2009;5(4):433–43.; Persson B.E., Kold Olesen T., Jensen J.K. Degarelix: a new approach for the treatment of prostate cancer. Neuroendocrinology 2009;90(3):235–44.; Klotz L., Boccon-Gibod L., Shore N.D. et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, openlabel, parallel-group phase III study in patients with prostate cancer. BJU Int 2008;102(11):1531–8.; Crawford E.D., Shore N.D., Moul J.W. et al. Long-term tolerability and efficacy of degarelix: 5-year results from a phase III extension trial with a 1-arm crossover from leuprolide to degarelix. Urology 2014;83(5):1122–8.; Klotz L., Miller K., Crawford E.D. et al. Disease control outcomes from analysis of pooled individual patient data from five comparative randomised clinical trials of degarelix versus luteinising hormonereleasing hormone agonists. Eur Urol 2014 Jan 9. pii: S0302–2838(13)01491–7.; Miller K., Rüssel C., Goble S. et al. Open-label, exploratory study of degarelix as second-line hormonal therapy in patients with prostate cancer (CS27). EAU 2013; Poster 678.; Van Poppel H., Klotz L. Gonadotropinreleasing hormone: an update review of the antagonists versus agonists. Int J Urol 2012;19(7):594–601.; Smith M.R., Klotz L., van der Meulen E. et al. Gonadotropin-releasing hormone blockers and cardiovascular disease risk: analysis of prospective clinical trials of degarelix. J Urol 2011;186(5): 1835–42.; Tanriverdi F., Gonzalez-Martinez D., Hu Y. et al. GnRH-I and GnRH-II have differential modulatory effects on human peripheral blood mononuclear cell proliferation and interleukin-2 receptor gamma-chain mRNA expression in healthy males. Clin Exp Immunol 2005;142(1):103–10.; Chen H.F., Jeung E.B., Stephenson M., Leung P.C. Human peripheral blood mononuclear cells express gonadotropinreleasing hormone (GnRH), GnRH receptor, and interleukin-2 receptor gamma-chain messenger ribonucleic acids that are regulated by GnRH in vitro. J Clin Endocrinol Metab 1999;84(2):743–50.; https://oncourology.abvpress.ru/oncur/article/view/399
-
3Academic Journal
-
4Academic Journal
Source: Research'n Practical Medicine Journal.
Subject Terms: РАК ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ, АНАЛОГИ И АНТАГОНИСТЫ ЛЮТЕИНИЗИРУЮЩЕГО ГОРМОНА РЕЛИЗИНГ ГОРМОНА, КАСТРАЦИОННАЯ РЕФРАКТЕРНОСТЬ, СЕРДЕЧНО-СОСУДИСТАЯ ПАТОЛОГИЯ, КАРДИОВАСКУЛЯРНЫЙ РИСК, 3. Good health
File Description: text/html
-
5Academic Journal
Source: Вопросы урологии и андрологии
Subject Terms: кастрационная рефрактерность, Castration-resistant, metastases, metastatic disease of ureter, prostate cancer, метастазы, метастатическое поражение мочеточника, рак предстательной железы
Availability: https://repository.rudn.ru/records/article/record/132047/
-
6Academic Journal
Authors: Nyushko K.M., Alekseev B.Ya., Kalpinsky A.S., Kaprin A.D.
Source: Onkourologiya
Subject Terms: рак предстательной железы, аналоги и антагонисты лютеинизирующего гормона рилизинг-гормона, дегареликс, кастрационная рефрактерность, сердечно-сосудистая патология, кардиоваскулярный риск
Availability: https://repository.rudn.ru/records/article/record/132572/
